^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VSV-GP154

    i
    Associations
    News

    Trials

    Company:
    Boehringer Ingelheim
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (NCT05846516)
    Phase 1
    Amal Therapeutics
    Recruiting
    Last update posted :
    06/03/2024
    Initiation :
    03/13/2023
    Primary completion :
    12/01/2026
    Completion :
    03/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154